Recent News

• 03.24.2026 - Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
• 03.06.2026 - Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
• 03.03.2026 - Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
• 02.24.2026 - Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
• 02.23.2026 - Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
• 02.17.2026 - Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
• 02.04.2026 - Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
• 02.03.2026 - Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
• 01.14.2026 - Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

Recent Filings

• 03.06.2026 - 8-K Current report
• 03.06.2026 - EX-99.1 EX-99.1
• 03.05.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2026 - 8-K Current report
• 03.03.2026 - EX-99.1 EX-99.1
• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 8-K Current report
• 02.18.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - EX-99.1 EX-99.1
• 02.04.2026 - 8-K Current report